Answers are grounded in this paper and cite their sources.
Intravenous donanemab 10 mg/kg can reduce amyloid deposits in AD despite having a shorter than expected half-life.
No takes yet. Share an insight, caveat, or question.
Lowe et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: